1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Chronic Disease (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Disease Attributes (1) · Immune System Diseases (1) · Multiple Sclerosis (1) · Nervous System Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Alemtuzumab (1) · Cladribine (1) · Natalizumab (1) · Rituximab (1) · ocrelizumab (1) · ofatumumab (1) · ublituximab (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (1)
George E. Georges, MD (1) · Jeffrey A. Cohen, MD (1) · Paolo A. Muraro, MD, PhD (1)
UM1AI109565 (1)